CABOZANTINIB | CABOZANTINIB | ATC L01EX07
ANTINEOPLASTIC TREATMENT OF PATIENTS WITH PROGRESSIVE METASTATIC MEDULLARY THYROID CANCER INHIBITOR OF TYROSINE KINASE | ORAL | VD 349 LITER PPB 99.7 PERCENT Cl 4.4 LITER / HOUR HT 55 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN AQUEOUS MEDIA | RET MET VEGFR-1 VEGFR-2 VEGFR-3 KIT TRKB FLT-3 AXL TIE-2 | Mast,stem cell growth factor receptor Kit UNIPROT P10721 KIT -- Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |